Phase III, randomised, prospective, multicenter double-blind, placebo-controlled study (ENGOT-EN5/GOG-3055/SIENDO)
Patients 18 years or older with histologically confirmed EC, who completed a single line of at least 12 weeks of taxane-platinum combination chemotherapy and achieved partial or complete response.
Selinexor (n=174) vs. PBO (n=89
Efficacy
ITT
mPFS: 5.7 vs 3.8 mos, HR: 0.76, p=0.126
TP53wt
mPFS: 13.7 vs 3.7 mos , HR:0.41, p=0.002
Safety
Grade3 Aes: Nausea (9.4% vs 0), neutropenia (8.8% vs 0), thrombocytopenia (7.0% vs 0)
